Form 4: Solen Therapeutics CEO Anish Bhatnagar Sells Shares to Cover Tax Obligations

Anish Bhatnagar, CEO of Soleno Therapeutics, sold shares of common stock on October 1, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On October 1, 2024, Anish Bhatnagar, the CEO of Soleno Therapeutics, sold 19,413 shares of common stock at a weighted average price of $49.3358.
• He also sold 2,220 shares of common stock at a weighted average price of $50.2479 on the same day.
• These sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Bhatnagar directly owns 719,553 shares of Soleno Therapeutics common stock, some of which are RSUs representing a contingent right to receive one share of common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Sales to cover tax obligations on vesting equity are common.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common practice across publicly traded companies.
• The size of the sale is relatively small compared to the total holdings, suggesting it's primarily for tax obligations rather than a strategic divestment.
• Comparable companies in the biotech sector often see similar insider transactions related to equity compensation.

Stakeholder Impact

• The stock sales may have a minor, temporary impact on the stock price due to the increased selling pressure.
• The transactions do not appear to have a significant impact on other stakeholders.

Key Dates